Vasculitis & polymyalgia rheumatica

The one-year infection risk among patients diagnosed with giant cell arteritis: use of antibiotics and hospitalisations

Rheumatology (Oxford)Published Nationwide observational cohort study

Main finding · Overall infectionsResult — go to the resultRelative risk 1.40 95% CI 1.38–1.42

Authors' conclusion

The use of antibiotic prescriptions and infection-related hospitalisations in the first year after a GCA diagnosis is high compared with the background population. The cumulative glucocorticoid dose is associated with the infection risk.

Study context

Population
Patients aged ≥50 years with a first-time giant cell arteritis (GCA) diagnosis, Danish National Patient Registry (1996–2022), and matched general population individuals
Participants
17,773 vs 177,730
Exposure
Patients with GCA vs matched general population individuals
  • GCAn = 17,773
  • Referencen = 177,730reference
Outcome
Overall infections (redeemed antibiotic prescriptions or infection-related hospitalisations), 1-year cumulative incidence proportion
Follow-up
1 year
Methodological detailsmatched 1:10 by sex and date of birth, pseudo-observation approach, registry-based
  • Matched 1:10 by sex and date of birth
  • Pseudo-observation approach
  • Registry-based

Main finding

Overall infections

Relative risk

1.40

95% CI 1.38–1.42

By group

GCA

52.4%

Cumulative incidence proportions (CIP) · 95% CI 51.7–53.2

GCAvs Reference
RR 1.40 (95% CI 1.38–1.42)

As reported in the abstract

Observational data: associations, not effects.

Further findings

OutcomeGCARR (95% CI)
Infection-related hospitalisations · 1 yearCIP 17.6% (95% CI 17.1–18.2)2.71 (2.61–2.82)

Risk factors for infection among patients with GCA

Higher cumulative GC doses, advanced age (≥70 years) and higher comorbidity associated with increased infection risk

Original publication

The one-year infection risk among patients diagnosed with giant cell arteritis: use of antibiotics and hospitalisations. Rheumatology (Oxford). Published 10 February 2024. doi:10.1093/rheumatology/keae107

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.